



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, March 13, 2025, 1:00pm
DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – Rachel Cain, PharmD, Chair
2. **Minutes - Approval of Minutes from the September 12, 2024 and January 15, 2025 meetings**
3. **New Drugs – Grid**
 - a) Aqneursa™ (levacetylleucine)
 - b) Danziten™ (nilotinib)
 - c) Itovebi™ (inavolisib)
 - d) Lazcluze™ (lazertinib)
 - e) Lodoco® (colchicine)
 - f) Miplyffa™ (arimoclomol)
 - g) Ojemda™ (tovorafenib) *
 - h) Voranigo® (vorasidenib)
 - i) Vyalev™ (foscarbidopa and foslevodopa)
 - j) Xdemvy™ (lotilaner)
 - k) Xolremdi® (mavorixafor)
 - l) Yorvipath® (palopegteriparatide)
4. **New Class Criteria**
 - a) Oral Oncology – Skin *
5. **Old Business**
 - a) Rezdifra™ (resmetirom)



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

6. Topics for Discussion

- a) Concurrent Use of Opioids and Benzodiazepines
- b) Concurrent Use of Opioids and Antipsychotics
- c) Overlaps in Opioids, Benzodiazepines and Antipsychotics
- d) Naloxone and Buprenorphine Utilization for Members on Opioids
- e) Antipsychotic Medications in Children
- f) Antidepressant Medications in Children
- g) Mood Stabilizer Medications in Children
- h) Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children

7. DUR Quarterly Newsletters (September and December 2024)

8. Prime Therapeutics Pipeline – Complete Pipeline available on WebPortal

9. Reports

- a) ProDUR
- b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
- c) Utilization Analysis

10. Adjournment